SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook, citing PC-market softness and manufacturing constraints, overshadowed its quarterly results and prompted analyst downgrades, driving a sharp selloff. Traders are divided between calling the drop an overreaction and buying the dip, versus expecting further declines as the turnaround remains uncertain.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention after shares sold off sharply despite a strong earnings beat, higher guidance and a planned 8-for-1 split, amid weakness across tech and memory stocks. Bulls call the drop an overreaction and point to AI-storage demand, while bears cite slowing growth and the risk that memory prices have peaked.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits sharp selloff followed a strong quarterly report but softer forward guidance, missed user-growth expectations, and managements warning that Google search referrals are declining; traders also worry that a planned logged-in experience could further limit traffic. The community is split between fears that AI-driven search changes and login restrictions threaten growth, and buyers who view the drop as an overreaction to a still-profitable business.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly earnings miss and heavy AI infrastructure spending, which drove concerns about cash flow and whether the investment will earn adequate returns, overshadowed accelerating AWS growth. Traders debated whether the selloff was overdone: many bought the dip and highlighted AWS, while others remained bearish over rising capex and uncertain AI payback; shares also staged a notable rebound.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a broad tech selloff, as Amazons heavy AI spending and cash-burn concerns and Intels weak outlook intensify doubts about the payoff from AI investment. Traders are divided between expecting further downside and seeing the sharp decline as an oversold dip-buying opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas preliminary reimbursement outlook, which points to a significant decline in DefenCaths contribution after the first quarter of 2027, has raised concerns about CorMedixs sales outlook. Those worries are compounded by Fresenius real-world data showing no significant difference in infection outcomes versus ClearGuard; traders debate whether the findings threaten DefenCaths adoption or are too preliminary to undermine its case.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a sharp rally and breakout, with traders speculating about a possible buyout and short covering; some connect the takeover talk to Novartiss weaker BTK results, but no deal is confirmed. Others point to upcoming earnings and BRIUMVIs growth and subcutaneous-development prospects as reasons for optimism, while debating whether the move reflects fundamentals or takeover hopes.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, led by Intels weak outlook and concerns about PC demand and tech earnings, is driving attention to SOXL; the funds 3x leverage has amplified the decline. Traders are divided between expecting further losses and buying the dip, with some arguing the AI-chip growth outlook remains intact.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical-infrastructure stocks, with traders citing broader sector weakness and concerns about dilution, capital needs, and customer concentration rather than a clear company-specific catalyst. Bulls point to ongoing data-center optics demand and upcoming earnings, while bears worry the decline may continue.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is under pressure as weak Amazon and Intel resultsalong with concerns about the cost and payoff of AI spendingfed a broader tech-led selloff. Traders are divided between expecting further declines and looking for a technical bounce, with volatility and stop-outs prominent in the discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?

Equity

Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. Q2 Sales Decline

(RTTNews) - Orchestra BioMed Holdings, Inc. (OBIO) announced Loss for second quarter of -$24.079 million...

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday

Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-orchestra-biomed-holdings-inc-stock...

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Growth in Short Interest

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling...

This account has been verified as an official OBIO representative.

Verified Account

Orchestra BioMed

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

Orchestra BioMed Holdings Inc

Bearish Sentiment

<ul class="summary-bullets"><li>BTIG turned “more constructive” on OBIO after management indicated the Backbeat trial remains on track to complete enrollment.</li><li>The trial is testing a therapy in patients with uncontrolled high blood pressure who need a pacemaker.</li><li>Barclays said LFST shareholders’ offering helps reduce the overhang from private equity ownership.</li></ul>Orchestra BioMed (OBIO) and LifeStance Health Group (LFST) were in focus on Thursday, with the stocks breaching their 52-week highs as Wall Street turned more positive on both healthcare stocks.Analysts cited progress toward a key clinical milestone at Orchestra and a reduction in LifeStance’s private-equity ownership overhang.At the time of writing, <a href="https://stocktwits.com/symbol/LFST">LFST shares</a> were up more than 4% and trading at the levels last seen in November 2021, while <a href="https://stocktwits.com/symbol/OBIO">OBIO shares</a> surged 11% to their highest levels since February 2025.<h2 class="st-heading-2">BTIG Sees Over 40% Potential Upside In OBIO</h2>Orchestra BioMed received an upgrade from BTIG on Thursday as the medical-device company approaches a key milestone for its late-stage hypertension study.BTIG analyst Marie Thibault upgraded Orchestra to ‘Buy’ from ‘Neutral’ with a $10 price target, representing more than 40% upside from current levels. The firm said it has become “more constructive” after management indicated the Backbeat trial remains on track to complete enrollment around the end of the third quarter.The trial, being conducted in partnership with Medtronic (MDT), is testing a therapy in patients with uncontrolled high blood pressure who need a pacemaker. Orchestra is targeting to enroll 284 patients, with primary results expected in the second quarter of 2027.BTIG said Orchestra has now met several conditions it previously required before upgrading the stock, including staying on schedule and securing non-dilutive funding.The company received <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-receives-20-million-payment-medtronic-under">$35 million</a> in strategic capital earlier this year, including $20 million from Medtronic and <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-receives-15-million-investment-ligand-under?">$15 million</a> from Ligand&nbsp;Pharmaceuticals (LGND).&nbsp;Orchestra ended June with $110 million in cash and investments, which it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-reports-second-quarter-2026-financial-results">expects</a> will fund operations into the fourth quarter of 2027.Retail sentiment surrounding OBIO on Stockwits turned ‘bullish’ from ‘bearish.’ The stock has gained around 40% so far this year.<h2 class="st-heading-2">Barclays Says LFST Stock Offering Reduces Private Equity Ownership Overhang</h2>LifeStance Health Group received a price target hike from Barclays on Thursday, a day after existing shareholders launched a secondary share offering.Barclays raised its price target on LifeStance to $15 from $13 and maintained an ‘Overweight’ rating, according to The Fly. This represents a 13% upside from current levels.On Wednesday, selling shareholders priced an offering of 22.25 million LifeStance shares at $12.35 per share, valuing the transaction at approximately $275 million. The offering price was at a 3.5% discount to the stock’s closing price of $12.80 on Tuesday.Barclays said the offering helps reduce the overhang from private equity ownership and added that LifeStance continues to execute well.Notably, LifeStance is not selling shares in the offering and will not receive any proceeds, which will instead go to the selling shareholders.Retail sentiment surrounding LFST on Stockwits turned ‘bullish’ from ‘neutral.’ The stock has surged 88% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/compass-ceo-robert-reffkin-says-upcoming-open-ai-anthropic-ip-os-are-already-boosting-luxury-housing-beyond-san-francisco/cZta1LyRJ6B">Compass CEO Robert Reffkin Says Upcoming OpenAI, Anthropic IPOs Are Already Boosting Luxury Housing Beyond San Francisco</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

LifeStance Health Group Inc

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Medtronic Plc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.01
Prev Close	$6.09
Open	$5.94
Dividend Yield	0.00%
50-Day Moving Average	$5.69
Beta	1.74
Avg. Volume	367,833.46
PE Ratio	-6.09

52-Week High	$6.50
52-Week Low	$3.46
Market Capitalization	$366.04M
EPS (Annual)	-$1.11
Price to Book	18.94
Revenue Per Employee	$389,325.58

Feed

News

Sentiment

Earnings

Fundamentals

Info

OBIO Fundamentals